NDAINTRAVITREALIMPLANTPriority Review
Approved
Jun 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
OZURDEX (dexamethasone) by AbbVie is corticosteroid hormone receptor agonists [moa]. First approved in 2009.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OZURDEX is a dexamethasone intravitreal implant approved in 2009 that delivers sustained corticosteroid therapy directly to the eye. It acts as a corticosteroid hormone receptor agonist to reduce inflammation and is indicated for multiple hematologic malignancies, solid tumors, chemotherapy-induced nausea/vomiting, sudden hearing loss, neurocysticercosis, COVID-19, and liposarcoma. The implant formulation enables prolonged drug exposure with reduced systemic exposure compared to oral dexamethasone.
$0.002BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D spend ($2M, 1,047 claims in 2023) signals a mature, niche positioning that may see headcount contraction on the brand team.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Started Oct 2026
42 enrolled
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started Jul 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Started May 2026
50 enrolled
Multiple Myeloma
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Started May 2026
500 enrolled
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Started May 2026
380 enrolled
Multiple Myeloma
Worked on OZURDEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.